Le Lézard
Classified in: Science and technology, Business
Subject: PER

The Goodman Group Announces Kevin Carden as Vice President of Investments


CHASKA, Minn., Nov. 6, 2024 /PRNewswire/ -- The Goodman Group has appointed Kevin Carden as vice president of investments at JBG Design & Development, an affiliate specializing in interior design services, project planning, development, acquisitions, and renovation services for The Goodman Group's managed communities.

The Goodman Group has appointed Kevin Carden as vice president of investments at JBG Design & Development.

Founded in 1965, The Goodman Group is a recognized national leader in developing and managing senior living and health care communities, residential communities, and commercial properties. With over 65 properties across eight states, the company provides homes for over 10,000 residents and employment for over 4,000 individuals. Platinum Service® is the customer philosophy of The Goodman Group and serves as each managed community's ongoing commitment to residents and families to deliver the highest-level quality of service.

Carden holds a master's degree in business administration with a focus on finance and international business and brings more than 25 years of experience in sourcing and completing real estate investments, conducting market research, and leveraging strategic investment platforms, particularly in the senior living industry. Carden will lead the origination, evaluation, and execution of beneficial acquisition and development opportunities for The Goodman Group and its managed partnerships, including The Goodman Family Operating Foundation (TGFOF).

The Goodman Group's investments are focused in both senior living and residential properties, as well as for-profit ventures and not-for-profit initiatives. The company aims to achieve strategic growth through the management and development of extraordinary communities, innovative technologies, and life enriching programs and services, while remaining committed to its mission and the mission of its nonprofit partners.

"I'm very excited to join The Goodman Group. I believe that The Goodman Group's ability to self-fund the entire equity stack, hold and execute long-term strategies, access tax-exempt financing for its partners, and maintain traditions of high-quality resident service for over half a century, uniquely positions the organization and its partners to aggressively pursue and complete acquisition and development opportunities," Carden says. "The Goodman Group is a long-standing organization with continual growth, and I'm excited to be part of the acquisitions and developments that are to come."

With careful consideration of third-party management opportunities, The Goodman Group will continue contributing to its legacy, building relationships, and planning for the future. The company takes pride in expanding its portfolio through acquisitions and new developments in select markets.

SOURCE The Goodman Group


These press releases may also interest you

at 15:30
Anthony "Tony" Van Heugten, the Chief Technology...

at 15:05
Merck , known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck's investigational antibody drug conjugate (ADC) that targets...

at 15:00
AbbVie announced groundbreaking results today from its latest Emotional Impact Report (EIR), a patient survey that provides an understanding of the mental...

at 12:55
Vertex Pharmaceuticals Incorporated today announced longer-term data for CASGEVYtm (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the...

at 12:35
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were...

at 12:35
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab),...



News published on and distributed by: